Hiroko Komatsu1, Kaori Yagasaki2, Takuhiro Yamaguchi3, Ayako Mori4, Hiromi Kawano5, Noriko Minamoto6, Orie Honma7, Kenji Tamura8. 1. Japanese Red Cross Kyushu International College of Nursing, 1-1 Asty Munakata-City, Fukuoka-Prefecture, 811-4157, Japan. Electronic address: h-komatsu@jrckicn.ac.jp. 2. Faculty of Nursing and Medical Care, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. Electronic address: yagasaki@sfc.keio.ac.jp. 3. Division of Biostatistics, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. Electronic address: yamaguchi@med.tohoku.ac.jp. 4. Division of Nursing, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: aymori@ncc.go.jp. 5. Nursing Department, Kanagawa Cancer Center, 2-3-1 Nakao, Yokohamashi, Kanagawa, 241-8515, Japan. Electronic address: gairai@kcch.jp. 6. Nursing Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken, 277-8577, Japan. Electronic address: nminamot@east.ncc.go.jp. 7. Division of Nursing, Showa University Hospital, 1-5-8, Hatanodai, Shinagawaku, Tokyo, 142-8666, Japan. Electronic address: ori-miya20@cmed.showa-u.ac.jp. 8. Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: ketamura@ncc.go.jp.
Abstract
PURPOSE:Adherence to medication is the most important challenge facing patients receiving oral anticancer treatment. This study aimed to evaluate the effects of a patient-centred medication self-management support programme in patients with metastatic breast cancer undergoing oral anticancer treatment. METHODS: This trial was a two-phased mixed-method randomised controlled study. Eligible participants were 155 patients with metastatic breast cancer newly prescribed an oral chemotherapy or targeted therapy agent. The intervention group received the patient-centred medication self-management support programme conducted by trained nurses. Primary outcome was adherence to medication at three months after the commencement of treatment, calculated by medication possession ratio (MPR). Secondary outcomes included self-efficacy, functional assessment, psychological distress, symptom severity and symptom interference, and patient satisfaction. After the completion of the intervention study, focus group interviews were conducted among intervention nurses. RESULTS: Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome. Regarding secondary outcomes, only general self-efficacy was significantly different in the two groups. In the qualitative study, the intervention nurses perceived improvement in the patients' self-efficacy, ability to anticipate the impact of treatment and adjust to life, and avoidance of loneliness. CONCLUSIONS: A significant effect of the programme was not found in the program because the adherence rate was high in both groups. Improvement in the patients' self-efficacy was observed both quantitatively and qualitatively. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR), Japan, UMIN000016597. (27 February 2015).
RCT Entities:
PURPOSE: Adherence to medication is the most important challenge facing patients receiving oral anticancer treatment. This study aimed to evaluate the effects of a patient-centred medication self-management support programme in patients with metastatic breast cancer undergoing oral anticancer treatment. METHODS: This trial was a two-phased mixed-method randomised controlled study. Eligible participants were 155 patients with metastatic breast cancer newly prescribed an oral chemotherapy or targeted therapy agent. The intervention group received the patient-centred medication self-management support programme conducted by trained nurses. Primary outcome was adherence to medication at three months after the commencement of treatment, calculated by medication possession ratio (MPR). Secondary outcomes included self-efficacy, functional assessment, psychological distress, symptom severity and symptom interference, and patient satisfaction. After the completion of the intervention study, focus group interviews were conducted among intervention nurses. RESULTS: Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome. Regarding secondary outcomes, only general self-efficacy was significantly different in the two groups. In the qualitative study, the intervention nurses perceived improvement in the patients' self-efficacy, ability to anticipate the impact of treatment and adjust to life, and avoidance of loneliness. CONCLUSIONS: A significant effect of the programme was not found in the program because the adherence rate was high in both groups. Improvement in the patients' self-efficacy was observed both quantitatively and qualitatively. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR), Japan, UMIN000016597. (27 February 2015).
Authors: Claire C Conley; McKenzie McIntyre; Nicole A Pensak; Filipa Lynce; Deena Graham; Roohi Ismail-Khan; Katherine Lopez; Susan T Vadaparampil; Suzanne C O'Neill Journal: Breast Cancer Res Treat Date: 2022-01-07 Impact factor: 4.872
Authors: Sarah M Belcher; Emily Mackler; Benyam Muluneh; Pamela K Ginex; Mary K Anderson; Elizabeth Bettencourt; Ryan K DasGupta; Jennifer Elliott; Erica Hall; Michelle Karlin; Diana Kostoff; Victoria K Marshall; Vanessa E Millisor; Maegan Molnar; Susan M Schneider; Janelle Tipton; Susan Yackzan; Kristine B LeFebvre; Kapeena Sivakumaran; Haya Waseem; Rebecca L Morgan Journal: Oncol Nurs Forum Date: 2022-06-17 Impact factor: 1.803
Authors: Evie E M Kolsteren; Esther Deuning-Smit; Alanna K Chu; Yvonne C W van der Hoeven; Judith B Prins; Winette T A van der Graaf; Carla M L van Herpen; Inge M van Oort; Sophie Lebel; Belinda Thewes; Linda Kwakkenbos; José A E Custers Journal: Cancers (Basel) Date: 2022-08-11 Impact factor: 6.575